Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib

Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotini...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jun-Li, Ren, Xiao-Cang, Lin, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037325/
https://www.ncbi.nlm.nih.gov/pubmed/24876785
http://dx.doi.org/10.2147/OTT.S49233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037325/
https://www.ncbi.nlm.nih.gov/pubmed/24876785
http://dx.doi.org/10.2147/OTT.S49233

Ejemplares similares